Show PDB file:   
         Plain Text   HTML   (compressed file size)
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(-)Asymmetric Unit
(-)Asym. Unit - sites
(-)Biological Unit 1
(-)Biol. Unit 1 - sites
collapse expand < >
Image Asymmetric Unit
Asymmetric Unit  (Jmol Viewer)
Image Asym. Unit - sites
Asym. Unit - sites  (Jmol Viewer)
Image Biological Unit 1
Biological Unit 1  (Jmol Viewer)
Image Biol. Unit 1 - sites
Biol. Unit 1 - sites  (Jmol Viewer)

(-) Description

Title :  CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
 
Authors :  C. Matijssen, M. C. Silva-Santisteban, I. M. Westwood, S. Siddique, V. P. Sheldrake, R. L. M. Van Montfort, J. Blagg
Date :  28 Nov 11  (Deposition) - 10 Oct 12  (Release) - 07 Nov 12  (Revision)
Method :  X-RAY DIFFRACTION
Resolution :  2.48
Chains :  Asym. Unit :  A
Biol. Unit 1:  A  (2x)
Keywords :  Transferase (Keyword Search: [Gene Ontology, PubMed, Web (Google))
 
Reference :  C. Matijssen, M. C. Silva-Santisteban, I. M. Westwood, S. Siddique, V. Choi, P. Sheldrake, R. L. M. Van Montfort, J. Blagg
Benzimidazole Inhibitors Of The Protein Kinase Chk2: Clarification Of The Binding Mode By Flexible Side Chain Docking And Protein-Ligand Crystallography
Bioorg. Med. Chem. V. 20 6630 2012
PubMed-ID: 23058106  |  Reference-DOI: 10.1016/J.BMC.2012.09.024

(-) Compounds

Molecule 1 - SERINE/THREONINE-PROTEIN KINASE CHK2
    ChainsA
    EC Number2.7.11.1
    EngineeredYES
    Expression SystemESCHERICHIA COLI
    Expression System PlasmidPTHREE-E
    Expression System StrainBL21(DE3)
    Expression System Taxid469008
    Expression System VariantROSETTA2 PLYSS
    Expression System Vector TypePLASMID
    FragmentKINASE DOMAIN, RESIDUES 210-531
    Organism CommonHUMAN
    Organism ScientificHOMO SAPIENS
    Organism Taxid9606
    Other DetailsHUMAN CDNA LIBRARY
    SynonymCHK2 CHECKPOINT HOMOLOG, CDS1 HOMOLOG, HUCDS1, HCDS1, CHECKPOINT KINASE 2

 Structural Features

(-) Chains, Units

  1
Asymmetric Unit A
Biological Unit 1 (2x)A

Summary Information (see also Sequences/Alignments below)

(-) Ligands, Modified Residues, Ions  (4, 12)

Asymmetric Unit (4, 12)
No.NameCountTypeFull Name
1A9U1Ligand/Ion2-{4-[(1-BENZYLPIPERIDIN-4-YL)METHOXY]PHENYL}-1H-BENZIMIDAZOLE-6-CARBOXAMIDE
2CL1Ligand/IonCHLORIDE ION
3EDO9Ligand/Ion1,2-ETHANEDIOL
4NO31Ligand/IonNITRATE ION
Biological Unit 1 (3, 22)
No.NameCountTypeFull Name
1A9U2Ligand/Ion2-{4-[(1-BENZYLPIPERIDIN-4-YL)METHOXY]PHENYL}-1H-BENZIMIDAZOLE-6-CARBOXAMIDE
2CL-1Ligand/IonCHLORIDE ION
3EDO18Ligand/Ion1,2-ETHANEDIOL
4NO32Ligand/IonNITRATE ION

(-) Sites  (12, 12)

Asymmetric Unit (12, 12)
No.NameEvidenceResiduesDescription
01AC1SOFTWARELEU A:375 , GLY A:403 , TYR A:404 , ASN A:405 , ARG A:406BINDING SITE FOR RESIDUE NO3 A1514
02AC2SOFTWARELEU A:277 , LYS A:278 , LEU A:280 , LYS A:287 , ILE A:288 , HOH A:2015BINDING SITE FOR RESIDUE EDO A1515
03AC3SOFTWARELYS A:249 , LEU A:301 , MET A:304 , GLU A:305 , GLY A:307 , GLU A:308 , LEU A:354 , GLN A:358 , THR A:367 , ASP A:368 , HOH A:2025BINDING SITE FOR RESIDUE A9U A1516
04AC4SOFTWARELYS A:278 , ILE A:288 , ASN A:290BINDING SITE FOR RESIDUE EDO A1517
05AC5SOFTWARELYS A:465 , PHE A:475 , GLU A:479 , ARG A:482 , HIS A:483 , PRO A:484 , HOH A:2082BINDING SITE FOR RESIDUE EDO A1518
06AC6SOFTWAREGLU A:219 , ASN A:290 , PHE A:291 , PHE A:292BINDING SITE FOR RESIDUE EDO A1519
07AC7SOFTWAREARG A:346 , VAL A:408 , HOH A:2085BINDING SITE FOR RESIDUE EDO A1520
08AC8SOFTWARELYS A:214 , GLU A:479 , ARG A:482 , HOH A:2003 , HOH A:2079BINDING SITE FOR RESIDUE EDO A1521
09AC9SOFTWAREGLN A:336 , ARG A:482BINDING SITE FOR RESIDUE EDO A1522
10BC1SOFTWAREARG A:240 , LYS A:241 , GLY A:400 , LYS A:472 , HOH A:2071 , HOH A:2086 , HOH A:2087BINDING SITE FOR RESIDUE EDO A1523
11BC2SOFTWARETHR A:242 , LYS A:244 , GLU A:429 , SER A:435 , LEU A:436 , LYS A:437BINDING SITE FOR RESIDUE EDO A1524
12BC3SOFTWAREVAL A:211 , TYR A:212 , ARG A:406BINDING SITE FOR RESIDUE CL A1525

(-) SS Bonds  (0, 0)

(no "SS Bond" information available for 4A9U)

(-) Cis Peptide Bonds  (0, 0)

(no "Cis Peptide Bond" information available for 4A9U)

 Sequence-Structure Mapping

(-) SAPs(SNPs)/Variants  (18, 18)

Asymmetric Unit (18, 18)
  dbSNPPDB
No.SourceVariant IDVariantUniProt IDStatusIDChainVariant
01UniProtVAR_019106E239KCHK2_HUMANDisease (PC)121908702AE239K
02UniProtVAR_019111I251FCHK2_HUMANDisease (PC)587780189AI251F
03UniProtVAR_019112R318HCHK2_HUMANDisease (PC)143611747AR318H
04UniProtVAR_019113T323PCHK2_HUMANDisease (PC)  ---AT323P
05UniProtVAR_019114Y327CCHK2_HUMANDisease (PC)587780194AY327C
06UniProtVAR_029154D347NCHK2_HUMANPolymorphism28909980AD347N
07UniProtVAR_066012H371YCHK2_HUMANPolymorphism531398630AH371Y
08UniProtVAR_073020Y390CCHK2_HUMANDisease (BC)200928781AY390C
09UniProtVAR_024572R406HCHK2_HUMANPolymorphism200649225AR406H
10UniProtVAR_022463S428FCHK2_HUMANPolymorphism137853011AS428F
11UniProtVAR_021117L436MCHK2_HUMANPolymorphism17882922AL436M
12UniProtVAR_021118N446KCHK2_HUMANPolymorphism17880867AN446K
13UniProtVAR_021119F447ICHK2_HUMANPolymorphism17881473AF447I
14UniProtVAR_021120I448SCHK2_HUMANPolymorphism17886163AI448S
15UniProtVAR_019115T476KCHK2_HUMANDisease (PC)  ---AT476K
16UniProtVAR_029155S500CCHK2_HUMANPolymorphism28909981AS500C
17UniProtVAR_021121E501KCHK2_HUMANPolymorphism17883172AE501K
18UniProtVAR_021122L512VCHK2_HUMANPolymorphism17882942AL512V

  SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)
Biological Unit 1 (18, 36)
  dbSNPPDB
No.SourceVariant IDVariantUniProt IDStatusIDChainVariant
01UniProtVAR_019106E239KCHK2_HUMANDisease (PC)121908702AE239K
02UniProtVAR_019111I251FCHK2_HUMANDisease (PC)587780189AI251F
03UniProtVAR_019112R318HCHK2_HUMANDisease (PC)143611747AR318H
04UniProtVAR_019113T323PCHK2_HUMANDisease (PC)  ---AT323P
05UniProtVAR_019114Y327CCHK2_HUMANDisease (PC)587780194AY327C
06UniProtVAR_029154D347NCHK2_HUMANPolymorphism28909980AD347N
07UniProtVAR_066012H371YCHK2_HUMANPolymorphism531398630AH371Y
08UniProtVAR_073020Y390CCHK2_HUMANDisease (BC)200928781AY390C
09UniProtVAR_024572R406HCHK2_HUMANPolymorphism200649225AR406H
10UniProtVAR_022463S428FCHK2_HUMANPolymorphism137853011AS428F
11UniProtVAR_021117L436MCHK2_HUMANPolymorphism17882922AL436M
12UniProtVAR_021118N446KCHK2_HUMANPolymorphism17880867AN446K
13UniProtVAR_021119F447ICHK2_HUMANPolymorphism17881473AF447I
14UniProtVAR_021120I448SCHK2_HUMANPolymorphism17886163AI448S
15UniProtVAR_019115T476KCHK2_HUMANDisease (PC)  ---AT476K
16UniProtVAR_029155S500CCHK2_HUMANPolymorphism28909981AS500C
17UniProtVAR_021121E501KCHK2_HUMANPolymorphism17883172AE501K
18UniProtVAR_021122L512VCHK2_HUMANPolymorphism17882942AL512V

  SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

(-) PROSITE Motifs  (1, 1)

Asymmetric Unit (1, 1)
 PROSITEUniProtKBPDB
No.IDACDescriptionIDLocationCountLocation
1PROTEIN_KINASE_STPS00108 Serine/Threonine protein kinases active-site signature.CHK2_HUMAN343-355  1A:343-355
Biological Unit 1 (1, 2)
 PROSITEUniProtKBPDB
No.IDACDescriptionIDLocationCountLocation
1PROTEIN_KINASE_STPS00108 Serine/Threonine protein kinases active-site signature.CHK2_HUMAN343-355  2A:343-355

(-) Exons   (10, 10)

Asymmetric Unit (10, 10)
 ENSEMBLUniProtKBPDB
No.Transcript IDExonExon IDGenome LocationLengthIDLocationLengthCountLocationLength
1.1bENST000003283541bENSE00001936528chr22:29137832-2913775776CHK2_HUMAN-00--
1.4aENST000003283544aENSE00001731305chr22:29130715-29130391325CHK2_HUMAN1-1071070--
1.9aENST000003283549aENSE00001674473chr22:29121355-29121231125CHK2_HUMAN107-148420--
1.10cENST0000032835410cENSE00001294552chr22:29121112-29120965148CHK2_HUMAN149-198500--
1.13ENST0000032835413ENSE00001778344chr22:29115473-2911538391CHK2_HUMAN198-228311A:209-22820
1.14cENST0000032835414cENSE00002163490chr22:29108005-29107897109CHK2_HUMAN228-264371A:228-253 (gaps)26
1.15ENST0000032835415ENSE00001690884chr22:29106047-2910599454CHK2_HUMAN265-282181A:265-28218
1.16ENST0000032835416ENSE00001600063chr22:29099554-2909949362CHK2_HUMAN283-303211A:283-30321
1.17aENST0000032835417aENSE00001751254chr22:29095925-29095826100CHK2_HUMAN303-336341A:303-33634
1.18dENST0000032835418dENSE00001742823chr22:29092975-2909288987CHK2_HUMAN337-365291A:337-36529
1.19aENST0000032835419aENSE00001610753chr22:29091861-29091698164CHK2_HUMAN366-420551A:366-420 (gaps)55
1.20aENST0000032835420aENSE00001744921chr22:29091230-29091115116CHK2_HUMAN420-459401A:420-45940
1.21ENST0000032835421ENSE00001669857chr22:29090105-2909002086CHK2_HUMAN459-487291A:459-48729
1.22cENST0000032835422cENSE00001622783chr22:29085203-2908512381CHK2_HUMAN488-514271A:488-51326
1.23gENST0000032835423gENSE00001550146chr22:29083974-29083732243CHK2_HUMAN515-543290--

(-) Sequences/Alignments

Asymmetric Unit
   Reformat: Number of residues per line =  ('0' or empty: single-line sequence representation)
  Number of residues per labelling interval =   
  UniProt sequence: complete  aligned part    
   Show mapping: SCOP domains CATH domains Pfam domains Secondary structure (by author)
SAPs(SNPs) PROSITE motifs Exons
(details for a mapped element are shown in a popup box when the mouse pointer rests over it)
Chain A from PDB  Type:PROTEIN  Length:288
 aligned with CHK2_HUMAN | O96017 from UniProtKB/Swiss-Prot  Length:543

    Alignment length:305
                                   218       228       238       248       258       268       278       288       298       308       318       328       338       348       358       368       378       388       398       408       418       428       438       448       458       468       478       488       498       508     
           CHK2_HUMAN   209 QSVYPKALRDEYIMSKTLGSGACGEVKLAFERKTCKKVAIKIISKRKFAIGSAREADPALNVETEIEILKKLNHPCIIKIKNFFDAEDYYIVLELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEEDCLIKITDFGHSKILGETSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFICLSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKKLLVVDPKARFTTEEALRHPWLQDEDMKRKFQDLLSEENESTALPQVLA 513
               SCOP domains d4a9ua_ A: automated     matches                                                                                                                                                                                                                                                                                  SCOP domains
               CATH domains ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- CATH domains
               Pfam domains ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Pfam domains
         Sec.struct. author ....hhhhhhheeeeeeee.----.eeeeee....eeeeeeeee.-----------.hhhhhhhhhhhhhhh.......eeeeee..eeeeee.....eehhhhhhhhh..hhhhhhhhhhhhhhhhhhhhhh.ee....hhh.eee........eee......ee.--hhhhhhhhh.....hhhhhhhh......hhhhhhhhhhhhhhhhhh...........hhhhhhhhh....hhhhhh..hhhhhhhhhhhh........hhhhhhhhhhhhhhhhhhhhhhhhhhhhh......... Sec.struct. author
                 SAPs(SNPs) ------------------------------K-----------F------------------------------------------------------------------H----P---C-------------------N-----------------------Y------------------C---------------H---------------------F-------M---------KIS---------------------------K-----------------------CK----------V- SAPs(SNPs)
                    PROSITE --------------------------------------------------------------------------------------------------------------------------------------PROTEIN_KINAS-------------------------------------------------------------------------------------------------------------------------------------------------------------- PROSITE
           Transcript 1 (1) Exon 1.13           ------------------------------------Exon 1.15         Exon 1.16            ---------------------------------Exon 1.18d  PDB: A:337-365   Exon 1.19a  PDB: A:366-420 (gaps) UniProt: 366-420     --------------------------------------Exon 1.21  PDB: A:459-487    Exon 1.22c  PDB: A:488-513 Transcript 1 (1)
           Transcript 1 (2) -------------------Exon 1.14c  PDB: A:228-253 (gaps)    --------------------------------------Exon 1.17a  PDB: A:303-336        -----------------------------------------------------------------------------------Exon 1.20a  PDB: A:420-459              ------------------------------------------------------ Transcript 1 (2)
                 4a9u A 209 MSVYPKALRDEYIMSKTLGS----EVKLAFERKTCKKVAIKIISK-----------DPALNVETEIEILKKLNHPCIIKIKNFFDAEDYYIVLELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEEDCLIKITDFGHSKIL--TSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFICLSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKKLLVVDPKARFTTEEALRHPWLQDEDMKRKFQDLLSEENESTALPQVLA 513
                                   218       228    |  238       248    |    -      |268       278       288       298       308       318       328       338       348       358       368      |378       388       398       408       418       428       438       448       458       468       478       488       498       508     
                                             228  233                 253         265                                                                                                           375  |                                                                                                                                       
                                                                                                                                                                                                   378                                                                                                                                       

   Legend:   → Mismatch (orange background)
  - → Gap (green background, '-', border residues have a numbering label)
    → Modified Residue (blue background, lower-case, 'x' indicates undefined single-letter code, labelled with number + name)
  x → Chemical Group (purple background, 'x', labelled with number + name, e.g. ACE or NH2)
  extra numbering lines below/above indicate numbering irregularities and modified residue names etc., number ends below/above '|'

 Classification and Annotation

(-) SCOP Domains  (1, 1)

Asymmetric Unit

(-) CATH Domains  (0, 0)

(no "CATH Domain" information available for 4A9U)

(-) Pfam Domains  (0, 0)

(no "Pfam Domain" information available for 4A9U)

(-) Gene Ontology  (52, 52)

Asymmetric Unit(hide GO term definitions)
Chain A   (CHK2_HUMAN | O96017)
molecular function
    GO:0005524    ATP binding    Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
    GO:0042802    identical protein binding    Interacting selectively and non-covalently with an identical protein or proteins.
    GO:0016301    kinase activity    Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.
    GO:0046872    metal ion binding    Interacting selectively and non-covalently with any metal ion.
    GO:0000166    nucleotide binding    Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.
    GO:0005515    protein binding    Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).
    GO:0042803    protein homodimerization activity    Interacting selectively and non-covalently with an identical protein to form a homodimer.
    GO:0004672    protein kinase activity    Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.
    GO:0019901    protein kinase binding    Interacting selectively and non-covalently with a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.
    GO:0004674    protein serine/threonine kinase activity    Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.
    GO:0016740    transferase activity    Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.
    GO:0031625    ubiquitin protein ligase binding    Interacting selectively and non-covalently with a ubiquitin protein ligase enzyme, any of the E3 proteins.
biological process
    GO:0000077    DNA damage checkpoint    A cell cycle checkpoint that regulates progression through the cell cycle in response to DNA damage. A DNA damage checkpoint may blocks cell cycle progression (in G1, G2 or metaphase) or slow the rate at which S phase proceeds.
    GO:0006975    DNA damage induced protein phosphorylation    The widespread phosphorylation of various molecules, triggering many downstream processes, that occurs in response to the detection of DNA damage.
    GO:0006977    DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest    A cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage and resulting in the stopping or reduction in rate of the cell cycle.
    GO:0006281    DNA repair    The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.
    GO:0000086    G2/M transition of mitotic cell cycle    The mitotic cell cycle transition by which a cell in G2 commits to M phase. The process begins when the kinase activity of M cyclin/CDK complex reaches a threshold high enough for the cell cycle to proceed. This is accomplished by activating a positive feedback loop that results in the accumulation of unphosphorylated and active M cyclin/CDK complex.
    GO:0006915    apoptotic process    A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
    GO:0007049    cell cycle    The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.
    GO:0051301    cell division    The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells.
    GO:0044257    cellular protein catabolic process    The chemical reactions and pathways resulting in the breakdown of a protein by individual cells.
    GO:0006974    cellular response to DNA damage stimulus    Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism.
    GO:1903926    cellular response to bisphenol A    Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bisphenol A stimulus.
    GO:0035690    cellular response to drug    Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a drug stimulus. A drug is a substance used in the diagnosis, treatment or prevention of a disease.
    GO:0006302    double-strand break repair    The repair of double-strand breaks in DNA via homologous and nonhomologous mechanisms to reform a continuous DNA helix.
    GO:0008630    intrinsic apoptotic signaling pathway in response to DNA damage    A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the detection of DNA damage, and ends when the execution phase of apoptosis is triggered.
    GO:0090307    mitotic spindle assembly    The aggregation, arrangement and bonding together of a set of components to form the spindle that contributes to the process of mitosis.
    GO:2000002    negative regulation of DNA damage checkpoint    Any process that stops, prevents, or reduces the frequency, rate or extent of a DNA damage checkpoint.
    GO:0071157    negative regulation of cell cycle arrest    Any process that decreases the rate, frequency, or extent of cell cycle arrest, the process in which the cell cycle is halted during one of the normal phases.
    GO:0018105    peptidyl-serine phosphorylation    The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine.
    GO:0016310    phosphorylation    The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide.
    GO:2000210    positive regulation of anoikis    Any process that activates or increases the frequency, rate or extent of anoikis.
    GO:0001934    positive regulation of protein phosphorylation    Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.
    GO:0045893    positive regulation of transcription, DNA-templated    Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription.
    GO:0046777    protein autophosphorylation    The phosphorylation by a protein of one or more of its own amino acid residues (cis-autophosphorylation), or residues on an identical protein (trans-autophosphorylation).
    GO:0006468    protein phosphorylation    The process of introducing a phosphate group on to a protein.
    GO:0050821    protein stabilization    Any process involved in maintaining the structure and integrity of a protein and preventing it from degradation or aggregation.
    GO:0042176    regulation of protein catabolic process    Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.
    GO:1901796    regulation of signal transduction by p53 class mediator    Any process that modulates the frequency, rate or extent of signal transduction by p53 class mediator.
    GO:0006355    regulation of transcription, DNA-templated    Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription.
    GO:0001302    replicative cell aging    The process associated with progression of the cell from its inception to the end of its lifespan that occurs as the cell continues cycles of growth and division.
    GO:0090399    replicative senescence    A cell aging process associated with the dismantling of a cell as a response to telomere shortening and/or cellular aging.
    GO:1902520    response to doxorubicin    Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a doxorubicin stimulus.
    GO:0010332    response to gamma radiation    Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gamma radiation stimulus. Gamma radiation is a form of electromagnetic radiation (EMR) or light emission of a specific frequency produced from sub-atomic particle interaction, such as electron-positron annihilation and radioactive decay. Gamma rays are generally characterized as EMR having the highest frequency and energy, and also the shortest wavelength, within the electromagnetic radiation spectrum.
    GO:0042770    signal transduction in response to DNA damage    A cascade of processes induced by the detection of DNA damage within a cell.
    GO:0072428    signal transduction involved in intra-S DNA damage checkpoint    A signal transduction process that contributes to an intra-S DNA damage checkpoint.
    GO:0006351    transcription, DNA-templated    The cellular synthesis of RNA on a template of DNA.
cellular component
    GO:0005794    Golgi apparatus    A compound membranous cytoplasmic organelle of eukaryotic cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack. The Golgi apparatus differs from the endoplasmic reticulum in often having slightly thicker membranes, appearing in sections as a characteristic shallow semicircle so that the convex side (cis or entry face) abuts the endoplasmic reticulum, secretory vesicles emerging from the concave side (trans or exit face). In vertebrate cells there is usually one such organelle, while in invertebrates and plants, where they are known usually as dictyosomes, there may be several scattered in the cytoplasm. The Golgi apparatus processes proteins produced on the ribosomes of the rough endoplasmic reticulum; such processing includes modification of the core oligosaccharides of glycoproteins, and the sorting and packaging of proteins for transport to a variety of cellular locations. Three different regions of the Golgi are now recognized both in terms of structure and function: cis, in the vicinity of the cis face, trans, in the vicinity of the trans face, and medial, lying between the cis and trans regions.
    GO:0016605    PML body    A class of nuclear body; they react against SP100 auto-antibodies (PML, promyelocytic leukemia); cells typically contain 10-30 PML bodies per nucleus; alterations in the localization of PML bodies occurs after viral infection.
    GO:0000781    chromosome, telomeric region    The terminal region of a linear chromosome that includes the telomeric DNA repeats and associated proteins.
    GO:0005654    nucleoplasm    That part of the nuclear content other than the chromosomes or the nucleolus.
    GO:0005634    nucleus    A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

 Visualization

(-) Interactive Views

Asymmetric Unit
  Complete Structure
    Jena3D(integrated viewing of ligand, site, SAP, PROSITE, SCOP information)
    WebMol | AstexViewer[tm]@PDBe
(Java Applets, require no local installation except for Java; loading may be slow)
    STRAP
(Java WebStart application, automatic local installation, requires Java; full application with system access!)
    RasMol
(require local installation)
    Molscript (VRML)
(requires installation of a VRML viewer; select preferred view via VRML and generate a mono or stereo PDF format file)
 
  Ligands, Modified Residues, Ions
    A9U  [ RasMol | Jena3D ]  +environment [ RasMol | Jena3D ]
    CL  [ RasMol | Jena3D ]  +environment [ RasMol | Jena3D ]
    EDO  [ RasMol | Jena3D ]  +environment [ RasMol | Jena3D ]
    NO3  [ RasMol | Jena3D ]  +environment [ RasMol | Jena3D ]
 
  Sites
    AC1  [ RasMol ]  +environment [ RasMol ]
    AC2  [ RasMol ]  +environment [ RasMol ]
    AC3  [ RasMol ]  +environment [ RasMol ]
    AC4  [ RasMol ]  +environment [ RasMol ]
    AC5  [ RasMol ]  +environment [ RasMol ]
    AC6  [ RasMol ]  +environment [ RasMol ]
    AC7  [ RasMol ]  +environment [ RasMol ]
    AC8  [ RasMol ]  +environment [ RasMol ]
    AC9  [ RasMol ]  +environment [ RasMol ]
    BC1  [ RasMol ]  +environment [ RasMol ]
    BC2  [ RasMol ]  +environment [ RasMol ]
    BC3  [ RasMol ]  +environment [ RasMol ]
 
  Cis Peptide Bonds
(no "Cis Peptide Bonds" information available for 4a9u)
 
Biological Unit
  Complete Structure
    Biological Unit 1  [ Jena3D ]

(-) Still Images

Jmol
  protein: cartoon or spacefill or dots and stick; nucleic acid: cartoon and stick; ligands: spacefill; active site: stick
Molscript
  protein, nucleic acid: cartoon; ligands: spacefill; active site: ball and stick

 Databases and Analysis Tools

(-) Databases

Access by PDB/NDB ID
  4a9u
    Family and Domain InformationProDom | SYSTERS
    General Structural InformationGlycoscienceDB | MMDB | NDB | OCA | PDB | PDBe | PDBj | PDBsum | PDBWiki | PQS | PROTEOPEDIA
    Orientation in MembranesOPM
    Protein SurfaceSURFACE
    Secondary StructureDSSP (structure derived) | HSSP (homology derived)
    Structural GenomicsGeneCensus
    Structural NeighboursCE | VAST
    Structure ClassificationCATH | Dali | SCOP
    Validation and Original DataBMRB Data View | BMRB Restraints Grid | EDS | PROCHECK | RECOORD | WHAT_CHECK
 
Access by UniProt ID/Accession number
  CHK2_HUMAN | O96017
    Comparative Protein Structure ModelsModBase
    Genomic InformationEnsembl
    Protein-protein InteractionDIP
    Sequence, Family and Domain InformationInterPro | Pfam | SMART | UniProtKB/SwissProt
 
Access by Enzyme Classificator   (EC Number)
  2.7.11.1
    General Enzyme InformationBRENDA | EC-PDB | Enzyme | IntEnz
    PathwayKEGG | MetaCyc
 
Access by Disease Identifier   (MIM ID)
  114480
    Disease InformationOMIM
  176807
    Disease InformationOMIM
 
Access by GenAge ID
  (no 'GenAge ID' available)
    Age Related InformationGenAge

(-) Analysis Tools

Access by PDB/NDB ID
    Domain InformationXDom
    Interatomic Contacts of Structural UnitsCSU
    Ligand-protein ContactsLPC
    Protein CavitiescastP
    Sequence and Secondary StructurePDBCartoon
    Structure AlignmentSTRAP(Java WebStart application, automatic local installation, requires Java; full application with system access!)
    Structure and Sequence BrowserSTING
 
Access by UniProt ID/Accession number
  CHK2_HUMAN | O96017
    Protein Disorder PredictionDisEMBL | FoldIndex | GLOBPLOT (for more information see DisProt)

 Related Entries

(-) Entries Sharing at Least One Protein Chain (UniProt ID)

UniProtKB/Swiss-Prot
        CHK2_HUMAN | O960171gxc 2cn5 2cn8 2w0j 2w7x 2wtc 2wtd 2wti 2wtj 2xbj 2xk9 2xm8 2xm9 2ycf 2ycq 2ycr 2ycs 2yiq 2yir 2yit 3i6u 3i6w 3va4 4a9r 4a9s 4a9t 4bda 4bdb 4bdc 4bdd 4bde 4bdf 4bdg 4bdh 4bdi 4bdj 4bdk

(-) Related Entries Specified in the PDB File

1gxc FHA DOMAIN FROM HUMAN CHK2 KINASE IN COMPLEX WITH A SYNTHETIC PHOSPHOPEPTIDE
2cn5 CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
2cn8 CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH DEBROMOHYMENIALDISINE
2w0j CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH NSC 109555 , A SPECIFIC INHIBITOR
2w7x CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019
2wtc CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2wtd CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2wti CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2wtj CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2xbj CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2xk9 STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 (CHK2) IN COMPLEX WITH INHIBITOR PV1533
2xm8 CO-CRYSTAL STRUCTURE OF A SMALL MOLECULE INHIBITOR BOUND TO THE KINASE DOMAIN OF CHK2
2xm9 STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
2ycf CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1531
2ycq CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1115
2ycr CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV976
2ycs CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV788
2yiq STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1322
2yir STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1352
2yit STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV1162, A NOVEL INHIBITOR
4a9r CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4a9s CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4a9t CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR